Anti-Nerve Growth Factor Market Outlook, Clinical Trial/Pipeline Analysis, Competitive Landscape, and Market Forecast Report – 2023 To 2031
Share With :
The nerve growth factor is a tumor tissue produced growth factor that promotes the growth and differentiation of sympathetic and sensory ganglia. It is the first growth factor to be identified. An elevated level of nerve growth factor leads to inflammation and peripheral nerve injury. The nerve growth factor is secreted in the body following stimulus (eg, chemical, thermal, or mechanical). Clinically, an elevated level of nerve growth factor in the body leads to chronic pain conditions like chronic headaches, diabetic neuropathy, interstitial cystitis, arthritis, pancreatitis, prostatitis, cancer pain, and noncancerous pain. Current pain management therapy has specific limitations and fails to meet current clinical needs. The discovery of nerve growth factors has been well characterized as essential mediators of pain management. Pharmacotherapies targeting this nerve growth factor are considered to have the potential to treat a variety of nociceptive and neuropathic pain conditions.
Currently, molecules targeting nerve growth factors are in the pipeline and are expected to enter the market in the forecast period. Tanezumab is most attractive and-NGF antibody, which is currently in phase 3 of clinical-stage development for various different indications, which includes back pain, cancer pain, musculoskeletal pain, and other pain. It is developed by Pfizer in collaboration with Eli Lilly & Company. In 2017, FDA granted fast track designation for tanezumab for the treatment of osteoarthritis and for chronic low back pain. Other anti-NGF antibody currently in the pipeline includes fulranumab, ASP6294, Fasinumab, and others. The entry of anti-NGF antibody into the market will fulfill the current unmet need for pain management therapeutics. The treatment algorithm for pain management will change significantly during the forecast period with the fasinumab and tanezumab holding a significant share of the market over the next decade. Increase in incidence and prevalence of inflammatory disease like osteoarthritis, etc and related disorders, growing demand for novel therapies and current unmet need from commercially available option drives the growth of anti-nerve growth factor antibody market during the forecast period. However, disappointing results of promising pipeline molecules hampers the growth of the market during the forecast period.
At the regional level, the global anti-nerve growth factor antibody has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. In terms of revenue, North America followed by Europe is a significant contributor to the global anti-nerve growth factor antibody market. The regional growth is driven by strong clinical pipeline, increasing research and drug development activities, presence of major players, and presence of developed healthcare infrastructure propels the growth of the market in the region. The Asia Pacific is third promising revenue contributor, which is expected to grow at a rapid pace in the upcoming year. Countries such as Japan, India, and China are major contributors for this market. Rising demands for novel therapies and emerging and huge population base countries such as China and India offers tremendous market opportunities for the anti-nerve growth factor antibody.
Some of the market players leading the global anti-nerve growth factor antibody market include Eli Lilly & Company, Pfizer, Regeneron Pharmaceuticals; Sanofi-aventis, Mitsubishi Tanabe Pharma Corporation, Teva Pharmaceutical Industries, Astellas Pharma, etc.
Global Anti-Nerve growth factor Market Outlook (Revenue, US$ Mn, 2019 – 2030)
Global Anti-Nerve growth factor Market Outlook (Revenue, US$ Mn, 2019 – 2030) By Region
This study employed a multi-step, mixed-method research approach that integrates:
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Secondary data for the market study was gathered from multiple credible sources, including:
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Primary interviews for this study involved:
Interviews were conducted via:
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
This ensured that the dataset used for modelling was clean, robust, and reliable.
The bottom-up approach involved aggregating segment-level data, such as:
This method was primarily used when detailed micro-level market data were available.
The top-down approach used macro-level indicators:
This approach was used for segments where granular data were limited or inconsistent.
To ensure accuracy, a triangulated hybrid model was used. This included:
This multi-angle validation yielded the final market size.
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Given inherent uncertainties, three scenarios were constructed:
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.